Beta-secretase 1 (BACE1)
Beta-secretase 1 (BACE1), also known as β-site amyloid precursor protein-cleaving enzyme 1, is a transmembrane aspartyl protease encoded by the BACE1 gene in humans.
Beta-secretase 1 (BACE1), also known as β-site amyloid precursor protein-cleaving enzyme 1, is a transmembrane aspartyl protease encoded by the BACE1 gene in humans. It is the rate-limiting enzyme responsible for the first proteolytic cleavage of amyloid precursor protein (APP), generating the soluble APP-beta fragment and the membrane-bound C99 stub that is subsequently cleaved by gamma-secretase to produce amyloid-beta (Aβ) peptides. The accumulation and aggregation of these Aβ peptides into plaques in the brain is a hallmark of Alzheimer's disease (AD) and forms the basis of the amyloid cascade hypothesis — currently the most widely accepted theoretical framework for understanding AD pathogenesis. Because BACE1 sits at a critical upstream node in this cascade, it has been intensively pursued as a therapeutic target for disease-modifying therapies in AD.
Beyond its role in amyloid processing, BACE1 is expressed broadly in the central nervous system and participates in the regulation of synaptic plasticity, myelination, and neuregulin signaling. Its inhibition, while therapeutically attractive, must therefore be carefully calibrated to avoid disrupting these physiological functions. This dual nature — as both a pathological driver and a functionally important enzyme — has made BACE1 one of the most challenging yet compelling targets in neuropharmacology, driving decades of medicinal chemistry, structural biology, and clinical investigation.
Where the papers sit
8 papers from the last 6 months study Beta-secretase 1 (BACE1) directly · updated from PubMed 5 Nov 2026
Study type 0 clinical trials · 4 human data · 4 preclinical
Themes one subject · 1 new direction
Those 8 are all about one subject.
-
BACE1 Across Disease Contexts
BACE1 appears in inhibitor discovery, Alzheimer’s biomarkers and imaging, cancer treatment resistance, and neuroprotection. Molecular dynamics and nanoprobe development address target inhibition and activity measurement, while plant compounds and polydatin are explored for protective effects. Other studies examine metabolic risk, retinal pathology, data reuse, and personalized therapy without a shared BACE1 mechanism. The group therefore offers no coherent research direction beyond broad biomedical investigation.
BACE1 is presented as a rectal-cancer chemosensitizer through cleavage of ST6GAL1
The rectal-cancer chemoradiation model assumes that ST6GAL1-mediated sialylation of TNFR1 promotes treatment resistance; instead, the study identifies BACE1 overexpression as a way to abrogate that resistance, assigning BACE1 a role in remodeling tumor-cell sialylation and improving chemoradiation response rather than serving only as an Alzheimer disease amyloid-related target or inhibitor target 42373231Jun.
Papers
The 8 papers from the last 6 months that study Beta-secretase 1 (BACE1) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
BACE1 Across Disease Contexts (8)
- Genetically predicted triglyceride levels and endometriosis risk: Mendelian randomization with exploratory multi-omics analyses. PloS one · 13 Aug 2026 PMID 42594068
- Leveraging molecular dynamics to unravel the inhibition mechanism of potential β-secretase (BACE1) inhibitors. Physical chemistry chemical physics : PCCP · 5 Aug 2026 PMID 42555228
- Therapeutic potential of Echinocactus grusonii and its associated endophytic fungus Aspergillus oryzae in neuroprotection: in vitro and in silico investigations. Scientific reports · 29 Jul 2026 PMID 42527432
- Retinal proteome changes mirror brain pathology and reveal synaptic and cytoskeletal dysfunction in Alzheimer's disease. Acta neuropathologica · 29 Jul 2026 PMID 42525245
- Polydatin inhibits hippocampal neurodegeneration in diabetic rats via modulation of oxidative stress and NF-kB/COX-2/IL-6 inflammatory pathway. Metabolic brain disease · 9 Jul 2026 PMID 42423809
- Beta-site Amyloid Precursor Protein Cleaving Enzyme 1 Overexpression Abrogates ST6GAL1 Mediated Rectal Cancer Chemoradiation Resistance. Cancer genomics & proteomics · 29 Jun 2026 PMID 42373231
- A 19F MRI/NIR-FL Nanoprobe for "Turn-On" Imaging of β-Secretase (BACE1) Activity in Alzheimer's Disease. Angewandte Chemie (International ed. in English) · 8 Jun 2026 PMID 42259598
- Turning failure into success: how artificial intelligence can help personalize therapies and re-use patient data. Purinergic signalling · 29 May 2026 PMID 42213219
By study type
Human data, design not indexed (4)
- Genetically predicted triglyceride levels and endometriosis risk: Mendelian randomization with exploratory multi-omics analyses. PloS one · 13 Aug 2026 PMID 42594068
- Leveraging molecular dynamics to unravel the inhibition mechanism of potential β-secretase (BACE1) inhibitors. Physical chemistry chemical physics : PCCP · 5 Aug 2026 PMID 42555228
- Retinal proteome changes mirror brain pathology and reveal synaptic and cytoskeletal dysfunction in Alzheimer's disease. Acta neuropathologica · 29 Jul 2026 PMID 42525245
- Turning failure into success: how artificial intelligence can help personalize therapies and re-use patient data. Purinergic signalling · 29 May 2026 PMID 42213219
Preclinical: animal, cell and lab studies (4)
- Therapeutic potential of Echinocactus grusonii and its associated endophytic fungus Aspergillus oryzae in neuroprotection: in vitro and in silico investigations. Scientific reports · 29 Jul 2026 PMID 42527432
- Polydatin inhibits hippocampal neurodegeneration in diabetic rats via modulation of oxidative stress and NF-kB/COX-2/IL-6 inflammatory pathway. Metabolic brain disease · 9 Jul 2026 PMID 42423809
- Beta-site Amyloid Precursor Protein Cleaving Enzyme 1 Overexpression Abrogates ST6GAL1 Mediated Rectal Cancer Chemoradiation Resistance. Cancer genomics & proteomics · 29 Jun 2026 PMID 42373231
- A 19F MRI/NIR-FL Nanoprobe for "Turn-On" Imaging of β-Secretase (BACE1) Activity in Alzheimer's Disease. Angewandte Chemie (International ed. in English) · 8 Jun 2026 PMID 42259598
Written from 8 PubMed abstracts, each one listed by PMID above. Published: 2026-07-02. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.